⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TVTX News
Travere Therapeutics, Inc. Common Stock
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
businesswire.com
TVTX
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
businesswire.com
TVTX
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
businesswire.com
TVTX
Form 8-K
sec.gov
TVTX
Travere Therapeutics Reports First Quarter 2026 Financial Results
businesswire.com
TVTX
Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK populations
globenewswire.com
TVTX
NTRA
Travere Therapeutics to Report First Quarter 2026 Financial Results
businesswire.com
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
globenewswire.com
TVTX
LGND